ly3434172
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 24, 2019 (NCT03936959)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
- Angiopoietin-related protein 3INHIBITOR
ANGPTL3 inhibitor
- Angiopoietin-like protein 8Immunity, passive
ANGPTL8 immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03936959 | Phase 1 | May 24, 2019 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1